Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 studyMeg Finch-Jones, Harpreet Wasan, Paul J. Ross et al.|The Lancet Oncology|2019Cited by 1.2k
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trialGary Middleton, John P. Neoptolemos, Paul Silcocks et al.|The Lancet Oncology|2014Cited by 374
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trialGary Middleton, John P. Neoptolemos, Daniel H. Palmer et al.|The Lancet Oncology|2017Cited by 73
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401Reinhard Dummer, Michele Maio, Pippa Corrie et al.|Journal of Clinical Oncology|2023Cited by 25
Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patientsPippa Corrie, N. Warner, A Mayer et al.|British Journal of Cancer|2002Cited by 16